The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InThe biotechnology sector is witnessing a significant surge in the development of treatments for Hidradenitis Suppurativa (HS), with over 24 companies currently working on innovative therapies. A comprehensive report by DelveInsight highlights substantial progress in the pipeline, driven by increased R&D investment and successful clinical outcomes. Notably, Novartis has secured FDA approval for its drug Cosentyx to treat pediatric cases of this chronic skin condition. Furthermore, late-stage clinical trials have yielded promising results for Incyte's povorcitinib and UCB's BIMZELX, signaling potential new market entries. Major pharmaceutical players, including AbbVie, Pfizer, and Amgen, are also actively competing in this space to expand their dermatology portfolios. These advancements are expected to diversify treatment options and drive growth for the involved companies through 2026.